426 related articles for article (PubMed ID: 19027287)
1. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
2. [BRCA1 and BRCA2 have reached the clinical medicine. The 10-year old finding of the genetic mutation makes it now possible to prevent breast cancer].
Loman N
Lakartidningen; 2004 Jun; 101(25):2172-7. PubMed ID: 15281304
[TBL] [Abstract][Full Text] [Related]
3. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
4. Rapid development of post-radiotherapy sarcoma and breast cancer in a patient with a novel germline 'de-novo' TP53 mutation.
Salmon A; Amikam D; Sodha N; Davidson S; Basel-Vanagaite L; Eeles RA; Abeliovich D; Peretz T
Clin Oncol (R Coll Radiol); 2007 Sep; 19(7):490-3. PubMed ID: 17572079
[TBL] [Abstract][Full Text] [Related]
5. The prevention of hereditary breast cancer.
Rodriquez E; Domchek SM
Semin Oncol; 2007 Oct; 34(5):401-5. PubMed ID: 17920894
[TBL] [Abstract][Full Text] [Related]
6. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
[TBL] [Abstract][Full Text] [Related]
7. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families.
Hartikainen JM; Kataja V; Pirskanen M; Arffman A; Ristonmaa U; Vahteristo P; Ryynänen M; Heinonen S; Kosma VM; Mannermaa A
Clin Genet; 2007 Oct; 72(4):311-20. PubMed ID: 17850627
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families.
Manoukian S; Peissel B; Pensotti V; Barile M; Cortesi L; Stacchiotti S; Terenziani M; Barbera F; Pasquini G; Frigerio S; Pierotti MA; Radice P; Della-Torre G
Eur J Cancer; 2007 Feb; 43(3):601-6. PubMed ID: 17224268
[TBL] [Abstract][Full Text] [Related]
9. Screening and follow-up of the patient at high risk for breast cancer.
Willey SC; Cocilovo C
Obstet Gynecol; 2007 Dec; 110(6):1404-16. PubMed ID: 18055740
[TBL] [Abstract][Full Text] [Related]
10. Considerations in genetic counseling for inherited breast cancer predisposition.
Robson ME; Offit K
Semin Radiat Oncol; 2002 Oct; 12(4):362-70. PubMed ID: 12382194
[TBL] [Abstract][Full Text] [Related]
11. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
Schwartz MD; Lerman C; Brogan B; Peshkin BN; Isaacs C; DeMarco T; Halbert CH; Pennanen M; Finch C
Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):1003-7. PubMed ID: 15824179
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
13. [Inherited predisposition to breast cancer: after the BRCA1 and BRCA2 genes, what next?].
Bonadona V; Lasset C
Bull Cancer; 2003 Jul; 90(7):587-94. PubMed ID: 12957799
[TBL] [Abstract][Full Text] [Related]
14. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
Thomassen M; Hansen TV; Borg A; Lianee HT; Wikman F; Pedersen IS; Bisgaard ML; Nielsen FC; Kruse TA; Gerdes AM
Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
[TBL] [Abstract][Full Text] [Related]
15. 18. Genetics of breast cancer.
Irving M; Elmslie F; Berg J
Int J Clin Pract; 2002 Nov; 56(9):677-82. PubMed ID: 12469982
[TBL] [Abstract][Full Text] [Related]
16. Management of women with a family history of breast cancer.
Curry P; Fentiman IS
Int J Clin Pract; 1999; 53(3):192-6. PubMed ID: 10665131
[TBL] [Abstract][Full Text] [Related]
17. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
18. Apparently "BRCA-related" breast and ovarian cancer patient with germline TP53 mutation.
Janavičius R; Andrėkutė K; Mickys U; Rudaitis V; Brasiūnienė B; Griškevičius L
Breast J; 2011; 17(4):409-15. PubMed ID: 21535297
[TBL] [Abstract][Full Text] [Related]
19. Results of a population-based screening for hereditary breast cancer in a region of North-Central Italy: contribution of BRCA1/2 germ-line mutations.
Seymour IJ; Casadei S; Zampiga V; Rosato S; Danesi R; Scarpi E; Falcini F; Strada M; Morini N; Naldoni C; Amadori D; Calistri D
Breast Cancer Res Treat; 2008 Nov; 112(2):343-9. PubMed ID: 18092194
[TBL] [Abstract][Full Text] [Related]
20. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms.
Nichols KE; Heath JA; Friedman D; Biegel JA; Ganguly A; Mauch P; Diller L
J Clin Oncol; 2003 Dec; 21(24):4505-9. PubMed ID: 14673037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
